Seoul Pharma files first corporate group status disclosure as QCP Group affiliate... Major shareholder holds 59.41%, stable financial structure but persistent operating loss
Seoul Pharma, as a member of QCP Group, filed this corporate group status disclosure for the first time since being newly designated as a large corporate group on May 1, 2026
Financial status: Total assets 71.75B KRW, total liabilities 30.70B KRW, total equity 41.05B KRW, debt ratio 74.8% (relatively stable), cash and equivalents 9.95B KRW
Earnings: Revenue 52.15B KRW, operating loss 1.28B KRW, but net income of 0.75B KRW due to other income; persistent operating loss is a risk factor for stock outlook
Ownership structure: Largest shareholder is affiliate 2018QCP13 Private Investment Limited Partnership (59.41%), total controlling party ownership 59.48%, stable control, minority shareholders 40.52%
Intra-group transactions: Receivables from Qro Holdings and Creo Estate totaling 4.48B KRW; no other material related-party transactions
[AI Summary]This disclosure is a routine filing due to new inclusion in a large business group, with no immediate positive or negative impact. However, sustained operating losses and high reliance on affiliates may pose long-term investment risks
KOSDAQ Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]